Edition:
United States

Cerus Corp (CERS.OQ)

CERS.OQ on NASDAQ Stock Exchange Global Market

2.50USD
18 Aug 2017
Change (% chg)

-- (--)
Prev Close
$2.50
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
219,693
52-wk High
$7.18
52-wk Low
$1.93

CERS.OQ

Chart for CERS.OQ

About

Cerus Corporation is a biomedical products company. The Company is engaged in developing and commercializing the INTERCEPT Blood System for blood safety. The Company operates through blood safety segment. The Company's INTERCEPT Blood System is based on its technology for controlling biological replication, and is designed to... (more)

Overall

Beta: 1.73
Market Cap(Mil.): $272.84
Shares Outstanding(Mil.): 109.14
Dividend: --
Yield (%): --

Financials

  CERS.OQ Industry Sector
P/E (TTM): -- 29.97 32.56
EPS (TTM): -0.61 -- --
ROI: -83.14 13.79 14.89
ROE: -111.57 16.63 16.13

BRIEF-Cerus Corp files for mixed shelf of up to $250 mln - SEC filing‍​

* Cerus Corp files for mixed shelf of up to $250 million - SEC filing‍​ Source text: (http://bit.ly/2wfbOni) Further company coverage:

Aug 04 2017

BRIEF-Cerus Q2 loss per share $0.16

* Q2 earnings per share view $-0.16 -- Thomson Reuters I/B/E/S

Aug 03 2017

BRIEF-Cerus enters into $40 mln amended growth capital agreement

* Cerus enters into $40 million amended growth capital agreement

Aug 02 2017

BRIEF-Cerus expands agreement with French National Blood Service

* Cerus announces expanded supply agreement with french national blood service

Aug 01 2017

BRIEF-Cerus provides update on U.S. Platelet additive solution supply

* Cerus provides update on U.S. Platelet additive solution (pas) supply

Jun 07 2017

BRIEF-Cerus provides U.S. business update

* A pending platelet additive solution shortage is expected to impact some U.S. blood centers producing intercept platelets

May 23 2017

BRIEF-First patient transfused in Cerus’ phase III RedeS study

* First patient transfused in Cerus’ phase III RedeS study evaluating safety and efficacy of the intercept red blood cell system

May 15 2017

BRIEF-Cerus provides update on Intercept red blood cell system

* Cerus announces exercise of additional BARDA contract options totaling $46.6 million to support intercept red blood cell system development

May 09 2017

BRIEF-Elk Creek Partners reports 5.17 pct passive stake in Cerus as of May 4 - SEC filing

* Elk Creek Partners reports 5.17 percent passive stake in Cerus Corp as of May 4 - SEC filing Source text : (http://bit.ly/2qhSndT) Further company coverage:

May 08 2017

BRIEF-Cerus Corp reports Q1 loss per share $0.18

* Q1 earnings per share view $-0.17 -- Thomson Reuters I/B/E/S

May 03 2017

Competitors

  Price Chg
Terumo Corp (4543.T) ¥4,195 +5.00
Grifols SA (GRLS.MC) €23.72 +0.43
Grifols SA (GRLSbn.MC) €17.34 +0.08

Earnings vs. Estimates